Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt‐Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia

Salarpour, Fatemeh; Goudarzipour, Kourosh; Mohammadi, Mohammad Hossein; Ahmadzadeh, Ahmad; Faraahi, Sara; Farsani, Mehdi Allahbakhshian

doi:10.1111/ahg.12210

Cited by 11 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, in the present research, a low CEBPA expression in the studied cohort was stated for the M6 case. However, a statistical significance of the difference in the CEBPA expression level between AML subtypes was confirmed probably neither in the present research nor by others [27,36], due to a small number of patients.…”

Section: Discussioncontrasting

confidence: 94%

“…Thus, downregulation of CEBPA may contribute to leukemogenesis in RUNX1-mutated AML. It stays in agreement with observation of Salarpour et al which previously demonstrated that CEBPA and RUNX1 expression levels are significantly positively correlated in both AML patients and healthy volunteers, although correlation was stronger in normal control cases [27]. Researchers suggested that the regulatory network between these genes could be disrupted in AML.…”

Section: Discussionsupporting

confidence: 92%

“…In the studied AML cohort, we stated the ubiquitous expression of CEBPA and c-MYC, the level of the expression varied substantially between cases. In previous research CEBPA overexpression was shown in vast percentage of AML cases [27,28], but a counter-observation was also published [29]. Also, in vast majority of AML patients c-MYC overexpression was shown [30].…”

Section: Discussionmentioning

confidence: 92%

See 2 more Smart Citations

Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development

et al. 2020

View full text Add to dashboard Cite

CEBPA and c-MYC genes belong to TF and play an essential role in hematologic malignancies development. Furthermore, these genes also co-regulate with RUNX1 and lead to bone marrow differentiation and may contribute to the leukemic transformation. Understanding the function and full characteristics of selected genes in the group of patients with AML can be helpful in assessing prognosis, and their usefulness as prognostic factors can be revealed. The aim of the study was to evaluate CEBPA and c-MYC mRNA expression level and to seek their association with demographical and clinical features of AML patients such as: age, gender, FAB classification, mortality or leukemia cell karyotype. Obtained results were also correlated with the expression level of the RUNX gene family. To assess of relative gene expression level the qPCR method was used. The expression levels of CEBPA and c-MYC gene varied among patients. Neither CEBPA nor c-MYC expression levels differed significantly between women and men (p=0.8325 and p=0.1698, respectively). No statistically significant correlation between age at the time of diagnosis and expression of CEBPA (p=0.4314) or c-MYC (p=0.9524) was stated. There were no significant associations between relative CEBPA (p=0.4247) or c-MYC (p=0.4655) expression level and FAB subtype and mortality among the enrolled patients (p=0.5858 and p=0.8437, respectively). However, it was observed that c-MYC and RUNX1 expression levels were significantly positively correlated (rS=0.328, p=0.0411). Overall, AML pathogenesis involves a complex interaction among CEBPA, c-MYC and RUNX family genes.

show abstract

Section: Discussioncontrasting

confidence: 94%

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As an intricate process, cell cycle regulation can undergo different alterations resulting in cell proliferation abnormalities and cancer progression. Proper cell division is ensured by various mechanisms controlling cell cycle [15,16]. These mechanisms include CDK regulation through cyclins, CDK inhibitors, and phosphorylation [17].…”

Section: (F) Expression Of P21 and P27 In T-all And B-all Patientsmentioning

confidence: 99%

Evaluation of P21Cip1 and P27Kip1 expression in de novo acute lymphoblastic leukemia patients

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) arises from an imbalanced proliferation and differentiation of lymphoid progenitors due to special chromosomal and epigenetic abnormalities affecting cell cycle regulation. The cyclin-dependent kinase inhibitor (CDKI) family has crucial functions in G1 progression and G1 to S entry regulation. Among CDKIs, P21 and P27 are able to exert remarkable effects on all CDKs. Hence, we investigated the expression levels of P21 and P27 in ALL patients to determine whether or not their expression had been altered. Materials and Methods: In the present study, we evaluated P21 and P27 expression in bone marrow and peripheral blood samples of 52 newly diagnosed ALL patients (30 males, 22 females) and 13 healthy normal controls (5 males, 8 females) using quantitative real-time PCR. Data were analyzed via SPSS (version 16) software and P<0.05 was assigned as the statistical significance level. Results: Our findings demonstrated lower expression levels of P21 and P27 in ALL patients compared with normal controls (8.33-and 1.69-fold change, respectively). P21 and P27 expression was significantly different between T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL) patients (P= 0.03). Conclusion: Since P21 and P27 are able to influence the activity of both cyclins and CDKs, it is postulated that decreased expression of these genes reduces P21-and P27-mediated suppressive effects on cyclins and CDKs. Therefore, these events facilitate the activation of cyclins and CDKs which may result in cancer progression in ALL patients. Abstract

show abstract

“…CEBPA is a single Exon gene located on the chromosome 19 q13.1 with the length of 2783 bp. This gene belongs to the basic region leucine zipper (bZIP) family 14,15 . Its mRNA is translated to two protein isoforms using the alternative AUG initiation codons: a full-length isoform of 42 kDa and an N-terminal truncated form of 30 kDa 16 .…”

Section: Introductionmentioning

confidence: 99%

Study on the significance correlation between CEBPA and Calreticulin at mRNA level diagnosed in de nevo AML patients

Salarpour¹,

Goudarzipour²,

Mohammadi

et al. 2020

Bangladesh J Med Sci

Self Cite

View full text Add to dashboard Cite

Objectives: Calreticulin (CALR) and CCAAT/enhancer binding protein (C/EBP) alpha (CEBPA) are two important multifunctional proteins which play different roles in regulation of hematopoiesis. Expressional changes of these genes were related to the malignancy. Methods: The present study aimed to investigate the expression levels of CALR and CEBPA genes in 96 de novo AML patients compared to 18 normal people as the control group through the Real-Time-PCR. Results: Results of the present study revealed that the expression of these genes was significantly higher in patients with AML than the normal group (P <0.0001). Furthermore, there was a significant and positive correlation between CALR and CEBPA (P= 0.001 and r= 0.348). Discussion: Higher level of CALR expression was expected, but the overexpression of CEBPA was on the contrary to its well-known role in the myeloid maturation. Based on the studies, CALR probably played roles in the expression of oncogenic CEBPA and it repressed the CEBPA translation in tumor suppressor gene (TSG). Conclusion: The present study first indicated the over-expression of CALR in AML patients and compared it with the healthy normal control group and also found a positive relationship between CALR and CEBPA expression in the AML patients. Bangladesh Journal of Medical Science Vol.19(4) 2020 p.730-736

show abstract

Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt‐Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia

Cited by 11 publications

References 41 publications

Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development

Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development

Evaluation of P21Cip1 and P27Kip1 expression in de novo acute lymphoblastic leukemia patients

Study on the significance correlation between CEBPA and Calreticulin at mRNA level diagnosed in de nevo AML patients

Contact Info

Product

Resources

About